CDK9 and Decreased total neutrophil count: Still, most pan-CDK inhibitors targeting CDK9, such as flavopiridol, have produced undesirable toxicities in preclinical studies and/or clinical trials, including particularly concerning blood toxicities like neutropenia (7).